This is an international website dedicated to HealthCare Professionals (outside the UK, ROI and the US) for educational purposes. Please note that it has not been validated nor is intended for clinical and diagnostic use.

Add a shortcut
on my desktop

Add a shortcut
to your phone

Prostatic inflammation

Persistent prostatic inflammation status plays a central role in both the development and progression of lower urinary tract symptoms (LUTS) / benign prostatic hyperplasia (BPH).1

Prostatic inflammation and development of BPH1

Chronic prostate inflammation (CPI) is identified as a key factor in the development of BPH. A chronic prostate inflammation is characterized by inflammatory cell infiltration within the prostatic tissue, predominantly consisting of T lymphocytes, as well as B lymphocytes and macrophages. These activated immune cells release pro-inflammatory cytokines, inducing the expression of several growth factors resulting in abnormal proliferation of epithelial and stromal prostate cells. The subsequent increased oxygen demand of these cells leads to local hypoxia producing low levels of reactive oxygen species (ROS) promoting angiogenesis and the production of additional growth factors.

In conclusion, prostatic inflammation plays a central role in the development and progression of BPH.1

1. De Nunzio C, et al. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol. 2020 Nov;38(11):2771-2779. doi: 10.1007/s00345-020-03106-1. Epub 2020 Feb 14. Erratum in: World J Urol. 2020 Jun 10;: PMID: 32060633; PMCID: PMC7644532.

cookie.btn